Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ImageneBio ( (IMA) ) just unveiled an update.
On November 1, 2025, ImageneBio, Inc. expanded its Board of Directors from six to seven members and appointed Joseph P. Slattery as a new director and Chair of the Audit Committee. This strategic move is part of the company’s efforts to strengthen its governance and oversight capabilities.
The most recent analyst rating on (IMA) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on ImageneBio stock, see the IMA Stock Forecast page.
Spark’s Take on IMA Stock
According to Spark, TipRanks’ AI Analyst, IMA is a Neutral.
Ikena Oncology’s overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.
To see Spark’s full report on IMA stock, click here.
More about ImageneBio
Average Trading Volume: 61,995
Technical Sentiment Signal: Sell
Current Market Cap: $92.14M
Learn more about IMA stock on TipRanks’ Stock Analysis page.